Can a Triple-Drug combo shrink Hard-to-Treat tumors?

NCT ID NCT07774611

NEW Not yet recruiting Disease control Sponsor: Hangzhou Sumgen Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tried other treatments. Participants receive the drugs by infusion every three weeks, and researchers monitor side effects, drug levels, and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SG1827 (an experimental drug) combined with an anti-PD-1/PD-L1 antibody and bevacizumab
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced solid tumors that have not responded to prior therapies.
What could go wrong: This is an early-phase trial, so the safety and effectiveness are not yet proven. The combination may cause significant side effects or may not work for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China
Dongguan People's Hospital

Dongguan, China
Fujian Cancer Hospital

Fuzhou, Fujian, China
Harbin Medical University Cencer Hospital

Haerbin, Heilongjiang, China
Hunan Cancer Hospital

Changsha, Hunan, China
Jilin Cancer Hospital

Changchun, Jilin, China
Sun Yat-sen University Cancer Center

Guanzhou, Guangdong, 510060, China
The Affiliated Hospital of Chengde Medical University

Chengde, Hebei, China
The First Affiliated Hospital of Henan Medical University

Xinxiang, Henan, China
The Second Xiangya Hospital of Central South University

Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.